



u-care
medical

Esercizio 1

Descrizione problema

Il PDF in allegato contiene un sottoinsieme di farmaci che potrebbero avere un impatto sulla funzionalità renale dei pazienti.

A partire dal PDF, estrarre per ogni farmaco le seguenti sezioni:

- *Clinical Use*
- *Dose in normal renal function*
- *Dose in renal impairment GFR (mL/min)*
- *Administration*

Chloroquine 201

Chloroquine

Clinical use <ul style="list-style-type: none">• Treatment and prophylaxis of malaria• Discoid and systemic lupus erythematosus• Rheumatoid arthritis	Dose in patients undergoing renal replacement therapies <table><tr><td>APD/CAPD</td><td>Not dialysed. Dose as in GFR <10 mL/min.</td></tr><tr><td>HD</td><td>Not dialysed. Dose as in GFR <10 mL/min.</td></tr><tr><td>HDF/High flux</td><td>Unknown dialysability. Dose as in GFR <10 mL/min.</td></tr><tr><td>CAV/VVHD</td><td>Not dialysed. Dose as in normal renal function.</td></tr></table>	APD/CAPD	Not dialysed. Dose as in GFR <10 mL/min.	HD	Not dialysed. Dose as in GFR <10 mL/min.	HDF/High flux	Unknown dialysability. Dose as in GFR <10 mL/min.	CAV/VVHD	Not dialysed. Dose as in normal renal function.		
APD/CAPD	Not dialysed. Dose as in GFR <10 mL/min.										
HD	Not dialysed. Dose as in GFR <10 mL/min.										
HDF/High flux	Unknown dialysability. Dose as in GFR <10 mL/min.										
CAV/VVHD	Not dialysed. Dose as in normal renal function.										
Dose in normal renal function <ul style="list-style-type: none">• Orally.• Malaria treatment: 600 mg, followed by 300 mg 6–8 hours later, then 300 mg/day for 2 days.• Malaria prophylaxis: 300 mg once a week on the same day each week (start 1 week before exposure to risk and continue until 4 weeks after leaving the malarial area).• SLE: 150 mg daily.• Rheumatoid arthritis: 150 mg daily; maximum 2.5 mg/kg	Important drug interactions <p>Potentially hazardous interactions with other drugs</p> <ul style="list-style-type: none">• Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone – avoid.• Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin – avoid; concentration of praziquantel reduced – consider increasing praziquantel dose.• Anti-depressants: possible increased risk of ventricular arrhythmias with citalopram and escitalopram.• Antiepileptics: antagonism of anticonvulsant effect.• Antimalarials: increased risk of convulsions with mefloquine; avoid with artemether/lumefantrine.• Antipsychotics: increased risk of ventricular arrhythmias with droperidol – avoid.• Ciclosporin: increases ciclosporin concentration – increased risk of toxicity.• Cytotoxics: possible increased risk of ventricular arrhythmias with bosutinib, ceritinib and panobinostat.• Digoxin: possibly increased concentration of digoxin.• Lanthanum: absorption possibly reduced by lanthanum, give at least 2 hours apart.										
Pharmacokinetics <table><tr><td>Molecular weight (daltons)</td><td>319.9 (515.9 as phosphate), (436 as sulphate)</td></tr><tr><td>% Protein binding</td><td>50–70</td></tr><tr><td>% Excreted unchanged in urine</td><td>42–47</td></tr><tr><td>Volume of distribution (L/kg)</td><td>>100</td></tr><tr><td>Half-life — normal/ESRF (hrs)</td><td>10–60 days / 5–50 days</td></tr></table>	Molecular weight (daltons)	319.9 (515.9 as phosphate), (436 as sulphate)	% Protein binding	50–70	% Excreted unchanged in urine	42–47	Volume of distribution (L/kg)	>100	Half-life — normal/ESRF (hrs)	10–60 days / 5–50 days	
Molecular weight (daltons)	319.9 (515.9 as phosphate), (436 as sulphate)										
% Protein binding	50–70										
% Excreted unchanged in urine	42–47										
Volume of distribution (L/kg)	>100										
Half-life — normal/ESRF (hrs)	10–60 days / 5–50 days										
Metabolism <p>Chloroquine is extensively metabolised in the liver, mainly to monodesethylchloroquine with smaller amounts of bisdesethylchloroquine (didesethylchloroquinine) and other metabolites being formed. Monodesethylchloroquine has been reported to have some activity against <i>Plasmodium falciparum</i>. Chloroquine and its metabolites are excreted in the urine, with about half of a dose appearing as unchanged drug and about 10% as the monodesethyl metabolite. Chloroquine may be detected in urine for several months.</p>											
Dose in renal impairment GFR (mL/min) <table><tr><td>20–50</td><td>Dose as in normal renal function.</td></tr><tr><td>10–20</td><td>Dose as in normal renal function.</td></tr><tr><td><10</td><td>50% of normal dose.</td></tr></table>	20–50	Dose as in normal renal function.	10–20	Dose as in normal renal function.	<10	50% of normal dose.	Administration <p>Reconstitution —</p> <p>Route • Oral, IV, IM/SC in rare cases</p> <p>Rate of administration • IV infusion: Administer dose of 10 mg/kg of chloroquine base in sodium chloride 0.9% by slow IV infusion over 8 hours followed by 3 further 8 hour infusions containing 5 mg base/kg (total dose 25 mg base/kg over 32 hours)</p>				
20–50	Dose as in normal renal function.										
10–20	Dose as in normal renal function.										
<10	50% of normal dose.										

Il contenuto di tali sezioni deve essere riportato in un foglio Excel aventi le seguenti colonne:

- Clinical Use
- Dose in normal renal function
- Dose in renal impairment GFR (mL/min)
- Administration

Aggiungere un ulteriore colonna (*Modified Dose based on GFR*) booleana (1/0) che indica se la dose del farmaco viene modificata per almeno un range di GFR indicati nella sezione *Dose in renal impairment GFR (mL/min)*.

Esempio:

Il farmaco **Chloroquine** prevede che per un $GFR < 10$, la dose indicata equivale al 50% di quella normale. In questo caso, nella colonna *Modified Dose based on GFR* dovrà essere indicato 1.

Deliverable:

Per lo svolgimento dell'esercizio è richiesto l'utilizzo di **Python** come linguaggio di programmazione. Utilizzare le librerie che si ritengono più opportune per risolvere il problema.

Fornire il codice usando un repository **Github** pubblico.